Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stylianos Papadakos

Interventional Cardiology Bayside, NY Medical Doctor

NPI 1487653051 CMS profile 113099

44-01 Francis Lewis Boulevard, Suite L3a, Bayside, NY 11361

Open in the dashboard

General payments

$11,097

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stylianos Papadakos of Bayside, NY is reported in the CMS Open Payments database as having received $11,097 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,615 21
2024 General $953 10
2023 General $732 9
2022 General $478 6
2021 General $1,071 14
2020 General $253 4
2019 General $5,995 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stylianos Papadakos
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Stylianos Papadakos were reported at $1,615. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Stylianos Papadakos Interventional Cardiology median Middle half National median
2019 $5,995 $1,097 $329–$3,048 $163
2020 $253 $473 $161–$1,480 $114
2021 $1,071 $677 $233–$1,827 $132
2022 $478 $978 $333–$2,724 $149
2023 $732 $1,136 $382–$2,986 $160
2024 $953 $1,181 $395–$3,326 $164
2025 $1,615 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,061 34 payments
  2. Boston Scientific Corporation $2,735 8 payments
  3. Abbott Laboratories $2,541 21 payments
  4. Shockwave Medical, Inc $827 5 payments
  5. Medtronic Vascular, Inc. $412 4 payments
  6. Abiomed $283 2 payments
  7. AstraZeneca Pharmaceuticals LP $236 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $229 6 payments
  9. Cook Medical LLC $125 1 payment
  10. Novartis Pharmaceuticals Corporation $107 6 payments
  11. Other $540 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,845 101 payments
  2. Travel and Lodging $2,740 16 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 2 payments
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL ATHERECTOMY $2,500 2 payments
  2. Mitra Clip system $2,089 14 payments
  3. SYMPLICITY G3 $1,286 15 payments
  4. Resolute Stents $1,044 12 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $827 5 payments
  6. COREVALVE EVOLUT R $562 4 payments
  7. Resolute Stents $277 3 payments
  8. JARDIANCE $229 6 payments
  9. BRILINTA $219 6 payments
  10. EMBOSHIELD NAV6 $193 1 payment
  11. Other $1,930 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,740

Median for Cardiology: 2,533

Drug cost

$304,189

Median for Cardiology: $485,213

Branded share of claims

25.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 104 $103,057
Jardiance Empagliflozin Brand 81 $81,206
Entresto Sacubitril/Valsartan Brand 69 $63,998
Xarelto Rivaroxaban Brand 17 $24,192
Brilinta Ticagrelor Brand 16 $15,103
Rosuvastatin Calcium Generic 239 $2,920
Metoprolol Succinate Generic 196 $2,886
Ezetimibe Generic 121 $1,959
Atorvastatin Calcium Generic 167 $1,758
Valsartan Generic 35 $1,289

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$94,843

Medicare's payments for the services billed

Medicare patients

261

Average age 76

Services billed

1,482

109 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 52%
Arthritis 52%
Heart failure 31%
Chronic kidney disease 31%
Atrial fibrillation 25%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $9
$9 104 —
PAXLOVID
  • PFIZER INC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record